Skip to main content

One in 3 Americans Takes Meds That May Cause Depression

More than one in three Americans may be taking prescription medications that can lead to depression or increase the risk of suicide, according to a new study conducted by researchers at the University of Illinois at Chicago (UIC).

And since many of these medications are common and not associated with depression — such as hormonal birth control medications, blood pressure and heart medications, proton pump inhibitors, antacids and painkillers — patients and clinicians may be unaware of the risks.

The findings are published in the Journal of the American Medical Association.

For the study, the research team looked at the medication use patterns of more than 26,000 adults from 2005 to 2014. The data was taken from the National Health and Nutrition Examination Survey. Their findings show that more than 200 commonly used prescription drugs have depression or suicide listed as potential side effects.

The research is the first to show that these drugs are often used concurrently and that concurrent use, called polypharmacy, is linked to an increased risk of depression.

The findings also show that about 15 percent of adults who simultaneously used three or more of these medications experienced depression while taking the drugs, compared with just 5 percent for those not using any of the drugs, 7 percent for those using one medication and 9 percent for those taking two drugs simultaneously.

The researchers found similar results for medications that listed suicide as a potential side effect. These findings remained strong even when the researchers excluded anyone using psychotropic medications, considered an indicator of underlying depression unrelated to medication use.

“The take away message of this study is that polypharmacy can lead to depressive symptoms and that patients and health care providers need to be aware of the risk of depression that comes with all kinds of common prescription drugs — many of which are also available over the counter,” said lead author Dr. Dima Qato, assistant professor of pharmacy systems, outcomes and policy in the UIC College of Pharmacy.

“Many may be surprised to learn that their medications, despite having nothing to do with mood or anxiety or any other condition normally associated with depression, can increase their risk of experiencing depressive symptoms, and may lead to a depression diagnosis.”

Qato notes that the findings reveal a trend of increasing polypharmacy for medications that list depression, particularly suicidal symptoms, as a potential adverse effect. This makes the need for awareness of depression as a potential side effect even more urgent.

The study finds that the use of any prescription medication listing depression as a potential side effect increased from 35 percent in the 2005 to 2006 period to 38 percent in the 2013 to 2014 period. The use of antacids with potential depression adverse effects, such as proton pump inhibitors and H2 antagonists, increased from 5 percent to 10 percent in the same period. Use of three or more drugs concurrently increased from around 7 percent to 10 percent.

For medications with suicide listed as a potential side effect, usage increased from 17 percent to 24 percent, and use of three or more drugs concurrently increased from 2 percent to 3 percent.

“People are not only increasingly using these medicines alone, but are increasingly using them simultaneously, yet very few of these drugs have warning labels, so until we have public or system-level solutions, it is left up to patients and health care professionals to be aware of the risks,” Qato said.

“With depression as one of the leading causes of disability and increasing national suicide rates, we need to think innovatively about depression as a public health issue, and this study provides evidence that patterns of medication use should be considered in strategies that seek to eliminate, reduce or minimize the impact of depression in our daily lives.”

Co-authors on the study are doctoral student Katharine Ozenberger of UIC and Columbia University’s Mark Olfson, M.D., M.P.H. Qato and Olfson both noted financial disclosures potentially relevant to the study.

Source: University of Illinois at Chicago



from Psych Central News https://ift.tt/2t7P4ot
via IFTTT

Become a patron of The Carlisle Wellness Network. Show everyone that you think this service is worth at least a buck. Go to; https://www.patreon.com/carlislewellness and pledge one dollar per month and help improve the resources it takes to gather the articles you see here as well as create fresh content including interviews an podcasts. We only need one dollar per month from all of our patrons to give The Carlisle Wellness Network a bright furture in the health and wellness social media ecosystem.

Comments

Popular posts from this blog

PET Imaging Agent Can ID Good Candidates for Depression Drug

A new brain imaging agent could reveal — before any treatment has been prescribed — whether a patient with major depressive disorder (MDD) is likely to respond to a particular antidepressant, according to a new study published in The Journal of Nuclear Medicine. No such marker is currently available in clinical psychiatry.Escitalopram (Lexapro), a selective serotonin reuptake inhibitor (SSRI), can be an effective MDD treatment for some patients, but not all. During  positron emission tomography (PET) test, the tracer 11C-DASB targets the serotonin transporter protein (5-HTT) in the amygdala of the brain, a region associated with emotional processing.In the study, patients shown to have less 5-HTT protein were those who later experienced relief from escitalopram.“MDD is a heterogeneous disorder, which makes it extremely difficult to treat effectively,” said researcher Mala R. Ananth, a graduate student at Stony Brook University in Stony Brook, N.Y.“Optimizing treatment is challenging a…

Reducing Alzheimer’s Stigma Could Enhance Research

A new study suggests ongoing research on Alzheimer’s disease may be challenged by the stigma associated with the disease. This concern comes from the results of a national survey which discovered people may be afraid to admit they have early stage Alzheimer’s because of fear of discrimination — especially potential limitations on their health insurance.Researchers say these fears can hopefully be overcome by the development of new policies to protect individuals. Nondisclosure of early symptoms that may or may not be Alzheimer’s hinders a individuals ability to obtain timely care. Additionally, a person may miss the opportunity to participate in clinical studies that discover potential therapies.The finding are the results of a national survey about what beliefs, attitudes and expectations are most often associated with Alzheimer’s disease. The survey results appear in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.“We found that concerns about discrimination a…

Hair Pulling, Nail Biting, Skin Peeling and Biting

All my life I’ve bitten my nails. It’s caused me a lot of trouble, especially with my bipolar mother who has always thought screaming and shouting at me (and often a smack when I was younger) would make me stop.At around 7 I also started biting and peeling the skin on my fingers which has caused a lot of social and health issues for me from being to ashamed to join in with prayers at school, to getting my fingers getting a fungal infection causing long lasting damage to my fingers.Soon after I started to pull out the tiny hairs on my legs during school assembles and by 12 I began to pull my eyebrow hair out.How can I stop doing this to myself? I don’t even realise I’m doing it half the time (I started biting the skin around my fingers just writing this and caused it to bleed a little). I’m afraid to bring this up with my parents because of how they have reacted in the past and I’m far too embarrassed to ask anyone I would typically trust. It has severally impacted how I interact with …